Christensen S, Bouguermouh S, Ilangovan K, Pride MW, et al. A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age. Vaccine 2023 Nov 15:S0264-410X(23)01296-3. doi: 10.1016/j.vaccine.2023.
PMID: 37977942